LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Strona główna・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

7.1 1

Buy Sell

Overview

Share price change

24h

Current

Min

7.03

Max

7.1

Key metrics
By Trading Economics
Income	7.8M 13M
Sales	-4M 159M
Profit margin	8.092
Employees	580
EBITDA	1.2M 30M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+171.79% upside

Market Stats
By TradingEconomics
Market Cap	-95M 1.4B
Previous open	6.1
Previous close	7.1

News Sentiment

By Acuity

41%

59%

129 / 374 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lis 2025, 21:36 UTC

Earnings

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 lis 2025, 21:22 UTC

Earnings

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 lis 2025, 00:00 UTC

Market Talk

India Inflation Poised to Hit New Low -- Market Talk

9 lis 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 lis 2025, 23:35 UTC

Market Talk

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 lis 2025, 21:05 UTC

Earnings

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 lis 2025, 21:04 UTC

Earnings

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 lis 2025, 21:03 UTC

Earnings

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 lis 2025, 20:49 UTC

Earnings

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 lis 2025, 20:49 UTC

Earnings

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 lis 2025, 20:45 UTC

Earnings

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 lis 2025, 20:45 UTC

Earnings

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 lis 2025, 20:42 UTC

Earnings

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 lis 2025, 20:42 UTC

Earnings

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 lis 2025, 20:41 UTC

Earnings

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 lis 2025, 20:41 UTC

Earnings

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 lis 2025, 20:39 UTC

Earnings

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 lis 2025, 20:39 UTC

Earnings

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 lis 2025, 20:38 UTC

Earnings

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 lis 2025, 20:38 UTC

Earnings

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 lis 2025, 20:38 UTC

Earnings

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 lis 2025, 13:10 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 lis 2025, 03:50 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 lis 2025, 03:41 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 lis 2025, 03:07 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 lis 2025, 22:36 UTC

Earnings

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 lis 2025, 22:22 UTC

Earnings

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q Rev $2.95B >CSU.T

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q Net $210M >CSU.T

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q EPS $9.89 >CSU.T

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

171.79% upside

12 Months Forecast

Average 19.27 USD 171.79%

High 30 USD

Low 8 USD

Based on 11 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

129 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.